Mahmoud A Ghannoum

List of Publications by Year
in descending order

244 papers	17,951 citations	17405 63 h-index	15683 125 g-index
255 all docs	255 docs citations	255 times ranked	15600 citing authors

#	Article	IF	Citations
1	Biofilm Formation by the Fungal Pathogen Candida albicans : Development, Architecture, and Drug Resistance. Journal of Bacteriology, 2001, 183, 5385-5394.	1.0	1,384
2	Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clinical Microbiology Reviews, 1999, 12, 501-517.	5.7	1,367
3	Characterization of the Oral Fungal Microbiome (Mycobiome) in Healthy Individuals. PLoS Pathogens, 2010, 6, e1000713.	2.1	869
4	Potential Role of Phospholipases in Virulence and Fungal Pathogenesis. Clinical Microbiology Reviews, 2000, 13, 122-143.	5.7	578
5	Mechanism of Fluconazole Resistance in Candida albicans Biofilms: Phase-Specific Role of Efflux Pumps and Membrane Sterols. Infection and Immunity, 2003, 71, 4333-4340.	1.0	462
6	International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clinical Infectious Diseases, 1997, 25, 43-59.	2.9	438
7	Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clinical Microbiology Reviews, 2001, 14, 643-658.	5.7	373
8	Resistance of Candida to azoles and echinocandins worldwide. Clinical Microbiology and Infection, 2019, 25, 792-798.	2.8	373
9	The Gut Microbiome as a Major Regulator of the Gut-Skin Axis. Frontiers in Microbiology, 2018, 9, 1459.	1.5	360
10	Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Molecular Microbiology, 2001, 39, 166-175.	1.2	319
11	The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	290
12	Oral Mycobiome Analysis of HIV-Infected Patients: Identification of Pichia as an Antagonist of Opportunistic Fungi. PLoS Pathogens, 2014, 10, e1003996.	2.1	278
13	Combination Treatment of Invasive Fungal Infections. Clinical Microbiology Reviews, 2005, 18, 163-194.	5.7	272
14	Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine. Antimicrobial Agents and Chemotherapy, 2003, 47, 82-86.	1.4	244
15	Experimental Pulmonary Aspergillosis Due toAspergillus terreus:Pathogenesis and Treatment of an Emerging Fungal Pathogen Resistant to Amphotericin B. Journal of Infectious Diseases, 2003, 188, 305-319.	1.9	233
16	Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. Journal of the American Academy of Dermatology, 2004, 50, 748-752.	0.6	211
17	Cloning and Disruption of caPLB1, a Phospholipase B Gene Involved in the Pathogenicity of Candida albicans. Journal of Biological Chemistry, 1998, 273, 26078-26086.	1.6	210
18	In vitro growth and analysis of Candida biofilms. Nature Protocols, 2008, 3, 1909-1924.	5.5	205

#	Article	IF	Citations
19	Microbial Contamination of Contact Lenses, Lens Care Solutions, and Their Accessories: A Literature Review. Eye and Contact Lens, 2010, 36, 116-129.	0.8	197
20	Mechanism of Fluconazole Resistance in Candida krusei. Antimicrobial Agents and Chemotherapy, 1998, 42, 2645-2649.	1.4	196
21	Fusarium and Candida albicans Biofilms on Soft Contact Lenses: Model Development, Influence of Lens Type, and Susceptibility to Lens Care Solutions. Antimicrobial Agents and Chemotherapy, 2008, 52, 171-182.	1.4	188
22	Rabbit Model of Candida albicans Biofilm Infection: Liposomal Amphotericin B Antifungal Lock Therapy. Antimicrobial Agents and Chemotherapy, 2004, 48, 1727-1732.	1.4	183
23	Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. Journal of Clinical Microbiology, 2004, 42, 3475-3482.	1.8	174
24	Onychomycosis: Diagnosis and definition of cure. Journal of the American Academy of Dermatology, 2007, 56, 939-944.	0.6	173
25	Distinct Roles for Dectin-1 and TLR4 in the Pathogenesis of Aspergillus fumigatus Keratitis. PLoS Pathogens, 2010, 6, e1000976.	2.1	159
26	The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohnâ€™s Diseaseâ€“Like Ileitis. Inflammatory Bowel Diseases, 2018, 24, 1005-1020.	0.9	159
27	Mycobiota in gastrointestinal diseases. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 77-87.	8.2	157
28	The RodA Hydrophobin on Aspergillus fumigatus Spores Masks Dectin-1â€“ and Dectin-2â€“Dependent Responses and Enhances Fungal Survival In Vivo. Journal of Immunology, 2013, 191, 2581-2588.	0.4	154
29	Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission ofCandida aurisand OtherCandidaSpecies. Infection Control and Hospital Epidemiology, 2017, 38, 1107-1109.	1.0	154
30	RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology (United Kingdom), 2004, 150, 267-275.	0.7	152
31	Effectiveness of Disinfectants Against Candida auris and Other Candida Species. Infection Control and Hospital Epidemiology, 2017, 38, 1240-1243.	1.0	146
32	Identification of Patients with Acute AIDS-Associated Cryptococcal Meningitis Who Can Be Effectively Treated with Fluconazole: The Role of Antifungal Susceptibility Testing. Clinical Infectious Diseases, 1996, 22, 322-328.	2.9	143
33	Increased Resistance of Contact Lens-Related Bacterial Biofilms to Antimicrobial Activity of Soft Contact Lens Care Solutions. Cornea, 2009, 28, 918-926.	0.9	143
34	Candida parapsilosisCharacterization in an Outbreak Setting. Emerging Infectious Diseases, 2004, 10, 1074-1081.	2.0	135
35	Alcohol Dehydrogenase Restricts the Ability of the Pathogen Candida albicans To Form a Biofilm on Catheter Surfaces through an Ethanol-Based Mechanism. Infection and Immunity, 2006, 74, 3804-3816.	1.0	135
36	Candidabiofilm: a well-designed protected environment. Medical Mycology, 2005, 43, 191-208.	0.3	132

#	Article	IF	Citations
37	Modification of Surface Properties of Biomaterials Influences the Ability of Candida albicans To Form Biofilms. Applied and Environmental Microbiology, 2005, 71, 8795-8801.	1.4	126
38	Interaction of Candida albicans with Adherent Human Peripheral Blood Mononuclear Cells Increases C. albicans Biofilm Formation and Results in Differential Expression of Pro- and Anti-Inflammatory Cytokines. Infection and Immunity, 2007, 75, 2612-2620.	1.0	122
39	Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology (United Kingdom), 2007, 153, 2373-2385.	0.7	121
40	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagnostic Microbiology and Infectious Disease, 2011, 70, 330-343.	0.8	117
41	In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	117
42	Identification of a Cryptococcus neoformans Cytochrome P450 Lanosterol 14Î±-Demethylase (Erg11) Residue Critical for Differential Susceptibility between Fluconazole/Voriconazole and Itraconazole/Posaconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 1162-1169.	1.4	109
43	Voriconazole -- better chances for patients with invasive mycoses. European Journal of Medical Research, 2002, 7, 242-56.	0.9	103
44	Candida biofilms: antifungal resistance and emerging therapeutic options. Current Opinion in Investigational Drugs, 2004, 5, 186-97.	2.3	103
45	Antifungal hydrogels. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12994-12998.	3.3	101
46	Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. Microbiology (United Kingdom), 2011, 157, 3232-3242.	0.7	101
47	Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species. Antimicrobial Agents and Chemotherapy, 2010, 54, 2225-2227.	1.4	95
48	Fungal Nail Infections (Onychomycosis): A Never-Ending Story?. PLoS Pathogens, 2014, 10, e1004105.	2.1	94
49	Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans. Microbiology (United Kingdom), 1997, 143, 331-340.	0.7	92
50	Mechanisms of Fungal Resistance. Drugs, 2002, 62, 1025-1040.	4.9	83
51	Characterization ofFusariumKeratitis Outbreak Isolates: Contribution of Biofilms to Antimicrobial Resistance and Pathogenesis. , 2012, 53, 4450.		83
52	Bacteriome and mycobiome associations in oral tongue cancer. Oncotarget, 2017, 8, 97273-97289.	0.8	82
53	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	1.4	81
54	Novel Antiseptic Urinary Catheters for Prevention of Urinary Tract Infections: Correlation of In Vivo and In Vitro Test Results. Antimicrobial Agents and Chemotherapy, 2009, 53, 5145-5149.	1.4	78

#	Article	IF	Citations
55	New investigational antifungal agents for treating invasive fungal infections. Expert Opinion on Investigational Drugs, 2000, 9, 1797-1813.	1.9	77
56	MyD88 Regulation of Fusarium Keratitis Is Dependent on TLR4 and IL-1R1 but Not TLR2. Journal of Immunology, 2008, 181, 593-600.	0.4	77
57	Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. International Journal of Medical Microbiology, 2010, 300, 265-270.	1.5	77
58	The mycobiome: Role in health and disease, and as a potential probiotic target in gastrointestinal disease. Digestive and Liver Disease, 2017, 49, 1171-1176.	0.4	75
59	Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. International Journal of Antimicrobial Agents, 2007, 30, 551-554.	1.1	74
60	Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. International Journal of Antimicrobial Agents, 2009, 33, 149-153.	1.1	73
61	Azole Resistance in Dermatophytes. Journal of the American Podiatric Medical Association, 2016, 106, 79-86.	0.2	73
62	Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. Journal of Antimicrobial Chemotherapy, 2018, 73, 2085-2088.	1.3	73
63	Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. Microbiology (United Kingdom), 2001, 147, 2585-2597.	0.7	72
64	A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. Journal of the American Academy of Dermatology, 2005, 53, 798-809.	0.6	67
65	Characterization of Bacterial Communities in Venous Insufficiency Wounds by Use of Conventional Culture and Molecular Diagnostic Methods. Journal of Clinical Microbiology, 2011, 49, 3812-3819.	1.8	65
66	Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. Journal of the American Academy of Dermatology, 1999, 40, S9-S13.	0.6	64
67	SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	64
68	A Murine Model of Contact Lensâ€“AssociatedFusariumKeratitis. , 2010, 51, 1511.		62
69	Novel role of a family of major facilitator transporters in biofilm development and virulence of Candida albicans. Biochemical Journal, 2014, 460, 223-235.	1.7	62
70	Relative Resistance of the Emerging Fungal Pathogen Candida auris and Other Candida Species to Killing by Ultraviolet Light. Infection Control and Hospital Epidemiology, 2018, 39, 94-96.	1.0	58
71	Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard. Journal of Clinical Microbiology, 2017, 55, 1262-1268.	1.8	55
72	Cutaneous hypersensitivity to Candida albicans in idiopathic vulvodynia. Contact Dermatitis, 2005, 53, 214-218.	0.8	54

#	Article	IF	Citations
73	Central Venous Catheterâ€“associatedNocardiaBacteremia in Cancer Patients. Emerging Infectious Diseases, 2011, 17, 1651-1658.	2.0	54
74	The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. Biomaterials, 2011, 32, 2689-2694.	5.7	54
75	Fungal Biofilms and Antimycotics. Current Drug Targets, 2005, 6, 887-894.	1.0	54
76	Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica, 2008, 93, 639-640.	1.7	53
77	Photodynamic Therapy with Pc 4 Induces Apoptosis of Candida albicans. Photochemistry and Photobiology, 2011, 87, 904-909.	1.3	53
78	Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. Journal of Antimicrobial Chemotherapy, 2003, 51, 1427-1429.	1.3	51
79	Parenteral Lipid Emulsion Induces Germination ofCandida albicansand Increases Biofilm Formation on Medical Catheter Surfaces. Journal of Infectious Diseases, 2009, 200, 473-480.	1.9	51
80	Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses, 2009, 52, 35-43.	1.8	50
81	Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clinical Microbiology and Infection, 2009, 15, 274-279.	2.8	49
82	Aspergillus Biofilm In Vitro and In Vivo. , 0, , 149-161.		49
83	Iron deprivation inducesEFG1-mediated hyphal development inCandida albicanswithout affecting biofilm formation. FEMS Yeast Research, 2008, 8, 744-755.	1.1	48
84	Effects of a Novel Probiotic Combination on Pathogenic Bacterial-Fungal Polymicrobial Biofilms. MBio, 2019, 10, .	1.8	48
85	VT-1161 Dosed Once Daily or Once Weekly Exhibits Potent Efficacy in Treatment of Dermatophytosis in a Guinea Pig Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1992-1997.	1.4	47
86	Metabolomics Reveals Differential Levels of Oral Metabolites in HIV-Infected Patients: Toward Novel Diagnostic Targets. OMICS A Journal of Integrative Biology, 2013, 17, 5-15.	1.0	46
87	Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status. Aids, 2018, 32, 1279-1287.	1.0	45
88	Successful Treatment of Fluconazole-Resistant Oropharyngeal Candidiasis by a Combination of Fluconazole and Terbinafine. Vaccine Journal, 1999, 6, 921-923.	2.6	45
89	Activity of TDT 067 (Terbinafine in Transfersome) against Agents of Onychomycosis, as Determined by Minimum Inhibitory and Fungicidal Concentrations. Journal of Clinical Microbiology, 2011, 49, 1716-1720.	1.8	44
90	Candida biofilms associated with CVC and medical devices. Mycoses, 2012, 55, 46-57.	1.8	44

#	Article	IF	Citations
91	Examining the importance of laboratory and diagnostic testing when treating and diagnosing onychomycosis. International Journal of Dermatology, 2018, 57, 131-138.	0.5	44
92	Single-Step PCR Using (GACA) 4 Primer: Utility for Rapid Identification of Dermatophyte Species and Strains. Journal of Clinical Microbiology, 2008, 46, 2641-2645.	1.8	42
93	Novel Quorum-Quenching Agents Promote Methicillin-Resistant Staphylococcus aureus (MRSA) Wound Healing and Sensitize MRSA to Î²-Lactam Antibiotics. Antimicrobial Agents and Chemotherapy, 2015, 59, 1512-1518.	1.4	42
94	A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1671-1679.	1.4	42
95	Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. International Journal of Dermatology, 2003, 42, 11-17.	0.5	41
96	Effect of Parenteral Antibiotic Administration on Establishment of Intestinal Colonization by Candida glabrata in Adult Mice. Antimicrobial Agents and Chemotherapy, 2005, 49, 438-440.	1.4	41
97	Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS ONE, 2018, 13, e0200285.	1.1	41
98	Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method. Antimicrobial Agents and Chemotherapy, 2008, 52, 4175-4177.	1.4	40
99	In Vitro Antifungal Activity of Naftifine Hydrochloride against Dermatophytes. Antimicrobial Agents and Chemotherapy, 2013, 57, 4369-4372.	1.4	40
100	The Role of Echinocandins in Candida Biofilmâ€“Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems. Clinical Infectious Diseases, 2015, 61, S618-S621.	2.9	39
101	A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. Clinical Infectious Diseases, 2021, 73, e1518-e1524.	2.9	39
102	Clinical Perspective Oropharyngeal Candidiasis in Patients with HIV: Suggested Guidelines for Therapy. AIDS Research and Human Retroviruses, 1999, 15, 1619-1623.	0.5	38
103	Biochemical characterization of terbinafine-resistantTrichophytonrubrumisolates. Medical Mycology, 2004, 42, 525-529.	0.3	38
104	Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans , Candida glabrata , and Candida parapsilosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 1543-1548.	1.4	38
105	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics, 2020, 9, 539.	1.5	38
106	Cutaneous hypersensitivity to Malassezia sympodialis and dust mite in adult atopic dermatitis with a textile pattern. Contact Dermatitis, 2006, 54, 92-99.	0.8	37
107	Interlaboratory Study of Quality Control Isolates for a Broth Microdilution Method (Modified CLSI) Tj ETQq1 1 0.784314 rgBT /Overlo 2006, 44, 4353-4356.	1.8	37
108	Endothelial Cell Injury Caused by Candida albicans Is Dependent on Iron. Infection and Immunity, 1998, 66, 191-196.	1.0	37

#	Article	IF	Citations
109	In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients. International Journal of Antimicrobial Agents, 2008, 31, 272-276.	1.1	36
110	Inhibition of Monocytic Interleukin-12 Production by Candida albicans via Selective Activation of ERK Mitogen-Activated Protein Kinase. Infection and Immunity, 2004, 72, 2513-2520.	1.0	35
111	Rhodococcus Bacteremia in Cancer Patients Is Mostly Catheter Related and Associated with Biofilm Formation. PLoS ONE, 2012, 7, e32945.	1.1	35
112	Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial. British Journal of Dermatology, 2008, 159, 711-713.	1.4	34
113	Cooperative Evolutionary Strategy between the Bacteriome and Mycobiome. MBio, 2016, 7, .	1.8	34
114	Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study. Biology of Blood and Marrow Transplantation, 2019, 25, 1511-1519.	2.0	33
115	Cloning and Characterization ofCAD1/AAF1, a Gene fromCandida albicansThat Induces Adherence to Endothelial Cells after Expression inSaccharomyces cerevisiae. Infection and Immunity, 1998, 66, 2078-2084.	1.0	33
116	Potentiation of Azole Antifungals by 2-Adamantanamine. Antimicrobial Agents and Chemotherapy, 2013, 57, 3585-3592.	1.4	32
117	Small-molecule AgrA inhibitors F12 and F19 act as antivirulence agents against Gram-positive pathogens. Scientific Reports, 2018, 8, 14578.	1.6	32
118	Candida albicans and Candida krusei Differentially Induce Human Blood Mononuclear Cell Interleukin-12 and Gamma Interferon Production. Infection and Immunity, 2000, 68, 2464-2469.	1.0	31
119	Hyphae and Yeasts of Candida albicans Differentially Regulate Interleukin-12 Production by Human Blood Monocytes: Inhibitory Role of C. albicans Germination. Infection and Immunity, 2001, 69, 4695-4697.	1.0	31
120	Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Medical Mycology, 2010, 48, 491-497.	0.3	31
121	Extracellular Phospholipases as Universal Virulence Factor in Pathogenic Fungi.. Medical Mycology Journal, 1998, 39, 55-59.	0.9	30
122	Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata. Frontiers in Cellular and Infection Microbiology, 2021, 11, 642358.	1.8	30
123	A second look at efficacy criteria for onychomycosis: clinical and mycological cure. British Journal of Dermatology, 2014, 170, 182-187.	1.4	29
124	The mycobiome in HIV. Current Opinion in HIV and AIDS, 2018, 13, 69-72.	1.5	29
125	Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2018, 4, 129.	1.5	29
126	Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	29

#	Article	IF	Citations
127	Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of Candida krusei. Antimicrobial Agents and Chemotherapy, 2008, 52, 1500-1502.	1.4	28
128	Shear stress modulates the thickness and architecture of Candida albicans biofilms in a phaseâ€dependent manner. Mycoses, 2009, 52, 440-446.	1.8	28
129	Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida biofilms. Journal of Antimicrobial Chemotherapy, 2012, 67, 149-153.	1.3	28
130	Treatment-resistant dermatophytosis: A representative case highlighting an emerging public health threat. JAAD Case Reports, 2020, 6, 1153-1155.	0.4	28
131	Molecular analysis of dermatophytes suggests spread of infection among household members. Cutis, 2013, 91, 237-45.	0.4	28
132	A Novel Actin Binding Drug withIn VivoEfficacy. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	27
133	New developments in chemotherapy for non-invasive fungal infections. Expert Opinion on Investigational Drugs, 2001, 10, 1501-1511.	1.9	26
134	Reactivity to trichophytin antigen in patients with onychomycosis: Effect of terbinafine. Journal of the American Academy of Dermatology, 2002, 46, 371-375.	0.6	26
135	Optimization of an Infected Shoe Model for the Evaluation of an Ultraviolet Shoe Sanitizer Device. Journal of the American Podiatric Medical Association, 2012, 102, 309-313.	0.2	26
136	Efficacy of Care Solutions Against Contact Lens-Associated Fusarium Biofilms. Optometry and Vision Science, 2012, 89, 382-391.	0.6	26
137	Therapeutic potential of TDT 067 (terbinafine in TransfersomeÂ®): a carrier-based dosage form of terbinafine for onychomycosis. Expert Opinion on Investigational Drugs, 2012, 21, 1549-1562.	1.9	26
138	Ability of Hydroxypropyl Chitosan Nail Lacquer To Protect against Dermatophyte Nail Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 1844-1848.	1.4	26
139	Fungal Translocation Is Associated with Immune Activation and Systemic Inflammation in Treated HIV. AIDS Research and Human Retroviruses, 2019, 35, 461-472.	0.5	26
140	Emerging Issues in Antifungal Resistance. Infectious Disease Clinics of North America, 2020, 34, 921-943.	1.9	26
141	Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis. Journal of Antimicrobial Chemotherapy, 2007, 59, 556-559.	1.3	25
142	Evaluation of the Morphological Effects of TDT 067 (Terbinafine in Transfersome) and Conventional Terbinafine on Dermatophyte Hyphae In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2012, 56, 2530-2534.	1.4	25
143	Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma. BBA Clinical, 2017, 7, 8-15.	4.1	24
144	The role of nondermatophyte molds in onychomycosis: diagnosis and treatment. Dermatologic Therapy, 2002, 15, 89-98.	0.8	23

#	Article	IF	Citations
145	Effect of growth of Candida spp. in the presence of various glucocorticoids on the adherence to human buccal epithelial cells. Mycopathologia, 1987, 98, 171-178.	1.3	22
146	Disruption of sphingolipid biosynthetic geneIPT1reducesCandida albicansadhesion and prevents activation of human gingival epithelial cell innate immune defense. Medical Mycology, 2011, 49, 1-9.	0.3	21
147	High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group. PLoS ONE, 2015, 10, e0131001.	1.1	21
148	Effects of voriconazole on Candida glabratain vitro. Journal of Antimicrobial Chemotherapy, 1999, 44, 109-112.	1.3	20
149	Candida albicans RHO1is required for cell viability in vitro and in vivo. FEMS Yeast Research, 2002, 2, 103-111.	1.1	20
150	Comparison between the Standardized Clinical and Laboratory Standards Institute M38-A2 Method and		

#	Article	IF	Citations
163	Antimicrobial Activity of B-Lock against Bacterial and Candida spp. Causing Catheter-Related Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2011, 55, 4430-4431.	1.4	16
164	A rabbit model for evaluation of catheter-associated fungal biofilms. Virulence, 2011, 2, 466-474.	1.8	16
165	Symbiosis and Dysbiosis of the Human Mycobiome. Frontiers in Microbiology, 2021, 12, 636131.	1.5	16
166	Antifungal susceptibility testing of yeasts: uses and limitations. Drug Resistance Updates, 2000, 3, 14-19.	6.5	15
167	Silicon Phthalocyanine 4 Phototoxicity in Trichophyton rubrum. Antimicrobial Agents and Chemotherapy, 2014, 58, 3029-3034.	1.4	15
168	Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants. Aids, 2017, 31, 81-88.	1.0	15
169	The monoclonal antibody Ca37, developed against Candida albicans alcohol dehydrogenase, inhibits the yeast in vitro and in vivo. Scientific Reports, 2020, 10, 9206.	1.6	15
170	Influence of gut microbiome on multiple myeloma: friend or foe?. , 2020, 8, e000576.		15
171	Gentian Violet Exhibits Activity against Biofilms Formed by Oral Candida Isolates Obtained from HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 3043-3045.	1.4	14
172	In VitroAntifungal Activity of ME1111, a New Topical Agent for Onychomycosis, against Clinical Isolates of Dermatophytes. Antimicrobial Agents and Chemotherapy, 2015, 59, 5154-5158.	1.4	14
173	Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis. Journal of the American Podiatric Medical Association, 2018, 108, 12-19.	0.2	14
174	Gut-derived bacterial toxins impair memory CD4+ T cell mitochondrial function in HIV-1 infection. Journal of Clinical Investigation, 2022, 132, .	3.9	13
175	The Mycobiome: Cancer Pathogenesis, Diagnosis, and Therapy. Cancers, 2022, 14, 2875.	1.7	13
176	The Natural Diyne-Furan Fatty Acid EV-086 Is an Inhibitor of Fungal Delta-9 Fatty Acid Desaturation with Efficacy in a Model of Skin Dermatophytosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 455-466.	1.4	12
177	The Role of Dectin-1 Signaling in Altering Tumor Immune Microenvironment in the Context of Aging. Frontiers in Oncology, 2021, 11, 669066.	1.3	12
178	The Fungal Biome of the Oral Cavity. Methods in Molecular Biology, 2016, 1356, 107-135.	0.4	12
179	A Microbiome-Driven Approach to Combating Depression During the COVID-19 Pandemic. Frontiers in Nutrition, 2021, 8, 672390.	1.6	11
180	Animal Models to Investigate Fungal Biofilm Formation. Methods in Molecular Biology, 2014, 1147, 141-157.	0.4	11

#	Article	IF	Citations
181	Candida tropicalis Infection Modulates the Gut Microbiome and Confers Enhanced Susceptibility to Colitis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 901-923.	2.3	11
182	Diagnosing Onychomycosis: Whatâ€™s New?. Journal of Fungi (Basel, Switzerland), 2022, 8, 464.	1.5	11
183	Anidulafungin. Infectious Diseases in Clinical Practice, 2005, 13, 165-178.	0.1	10
184	Voriconazole and Caspofungin Cidality Against Non-Albicans Candida Species. Infectious Diseases in Clinical Practice, 2007, 15, 250-253.	0.1	10
185	Comparison of thein vitroactivity of terbinafine and lanoconazole against dermatophytes. Mycoses, 2009, 53, 311-3.	1.8	10
186	Repeated exposure of Candida spp. to miconazole demonstrates no development of resistance. Mycoses, 2011, 54, e175-e177.	1.8	10
187	Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay. Dermatology and Therapy, 2016, 6, 69-75.	1.4	10
188	Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: Improved understanding and new strategic approach with sargramostim. Clinical Immunology, 2021, 228, 108731.	1.4	10
189	Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata. Mycopathologia, 1986, 95, 175-181.	1.3	9
190	Admission to the Intensive Care Unit is Associated With Changes in the Oral Mycobiome. Journal of Intensive Care Medicine, 2017, 32, 278-282.	1.3	9
191	Quorum-Sensing Dysbiotic Shifts in the HIV-Infected Oral Metabiome. PLoS ONE, 2015, 10, e0123880.	1.1	9
192	Clinical Effects of Gamma-Radiation-ResistantAspergillus sydowiion Germ-Free Mice Immunologically Prone to Inflammatory Bowel Disease. Journal of Pathogens, 2016, 2016, 1-7.	0.9	8
193	A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails. Mycoses, 2019, 62, 494-501.	1.8	8
194	Intestinal Stem Cell Niche Defects Result in Impaired 3D Organoid Formation in Mouse Models of Crohn's Disease-like Ileitis. Stem Cell Reports, 2020, 15, 389-407.	2.3	8
195	A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	8
196	In Vitro and In Vivo Antifungal Activity of AmBisome Compared to Conventional Amphotericin B and Fluconazole against Candida auris. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	8
197	GM-CSF: Orchestrating the Pulmonary Response to Infection. Frontiers in Pharmacology, 2021, 12, 735443.	1.6	8
198	Fungal Phospholipase Activity and Susceptibility to Lipid Preparations of Amphotericin B. Antimicrobial Agents and Chemotherapy, 2001, 45, 3231-3233.	1.4	7

#	Article	IF	Citations
199	Fungal Biofilms in the Clinical Lab Setting. Current Fungal Infection Reports, 2010, 4, 137-144.	0.9	7
200	Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint. Antimicrobial Agents and Chemotherapy, 2015, 59, 1759-1766.	1.4	7
201	Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111. Journal of Clinical Microbiology, 2016, 54, 662-665.	1.8	7
202	Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics, 2022, 11, 324.	1.5	7
203	Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US. Journal of Drugs in Dermatology, 2021, 20, 1076-1084.	0.4	7
204	Susceptibility testing of dermatophytes. Current Fungal Infection Reports, 2009, 3, 142-146.	0.9	6
205	Efficacy of NVC-422 in the treatment of dermatophytosis caused byTrichophyton mentagrophytesusing a guinea pig model. International Journal of Dermatology, 2013, 52, 567-571.	0.5	6
206	A Novel Transdermal Application for Clearing Skin Colonization by Candida auris. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	6
207	Indole-3-acetic acid synthesized through the indole-3-pyruvate pathway promotes Candida tropicalis biofilm formation. PLoS ONE, 2020, 15, e0244246.	1.1	6
208	Evaluation of Microbiome Alterations Following Consumption of BIOHM, a Novel Probiotic. Current Issues in Molecular Biology, 2021, 43, 2135-2146.	1.0	6
209	The Human Mycobiome and its Impact on Health and Disease. Current Fungal Infection Reports, 2013, 7, 345-350.	0.9	5
210	Updates on Therapeutic Strategies Against Candida (and Aspergillus) Biofilm Related Infections. Advances in Experimental Medicine and Biology, 2016, 931, 95-103.	0.8	5
211	Evaluation of the Efficacy of ME1111 in the Topical Treatment of Dermatophytosis in a Guinea Pig Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 2343-2345.	1.4	5
212	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular Biology, 2022, 44, 2015-2028.	1.0	5
213	Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. Antibiotics, 2022, 11, 722.	1.5	5
214	N-Acetylcysteine Lock Solution Prevents Catheter-Associated Bacteremia in Rabbits. International Journal of Artificial Organs, 2012, 35, 893-897.	0.7	4
215	Candida albicans Biofilm Development and Its Genetic Control. , 0, , 99-114.		4
216	Evaluation of the Ability of a Novel Miconazole Formulation To Penetrate Nail by Using Three In Vitro Nail Models. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	4

#	Article	IF	Citations
217	Effect of an Emollient on the Mycobiome of Atopic Dermatitis Patients. Journal of Drugs in Dermatology, 2018, 17, 1039-1048.	0.4	4
218	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	2.9	3
219	Fungal Biofilms:In VivoModels for Discovery of Anti-Biofilm Drugs. , 2015, , 33-49.		3
220	The Mycobiome: Impact on Health and Disease States. , 2017, , 845-854.		3
221	A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicans. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
222	Do Antifungals and Local Anesthetic Affect the Efficacy of Antibiotic Dipping Solution?. Journal of Sexual Medicine, 2021, 18, 966-973.	0.3	3
223	Fungal Biofilms: Agents of Disease and Drug Resistance. , 0, , 177-185.		3
224	Yeast susceptibility testing: reference methods and commercial test systems. Clinical Microbiology Newsletter, 2001, 23, 131-135.	0.4	2
225	Transplant Outcomes and Toxicities Are Associated with Changes in Relative Abundance, Diversity and Richness of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study. Biology of Blood and Marrow Transplantation, 2019, 25, S414-S415.	2.0	2
226	Characterization and functional analysis of microbiome in bladder cancer.. Journal of Clinical Oncology, 2022, 40, 541-541.	0.8	2
227	Etiology of tinea capitis in the United States and Puerto Rico, Latin America and Mexico, and India. Journal of the American Academy of Dermatology, 2004, 50, P100.	0.6	1
228	Microbiome: Its Impact Is Being Revealed!. Current Clinical Microbiology Reports, 2017, 4, 78-87.	1.8	1
229	Assessing the Severity and Impact of Oral Mucositis after Autologous Transplantation for Myeloma: A Prospective Pilot Study Comparing the Patient-Reported Quality of Life and Objective Evaluation by a Healthcare Professional. Biology of Blood and Marrow Transplantation, 2018, 24, S266-S267.	2.0	1
230	Oral Cytokine Levels Are More Linked to Levels of Plasma and Oral HIV-1 RNA Than to CD4+ T-Cell Counts in People With HIV. Open Forum Infectious Diseases, 2020, 7, ofaa047.	0.4	1
231	Heparin-mediated antibiotic delivery from an electrochemically-aligned collagen sheet. Bio-Medical Materials and Engineering, 2021, 32, 159-170.	0.4	1
232	Candida Biofilms: Development, Architecture, and Resistance. , 0, , 115-134.		1
233	The Microbiome: More than Bacteria. Microbe Magazine, 2010, 5, 459-459.	0.4	1
234	CYTOKINE RESPONSE OF ATOPIC DERMATITIS PATIENTS TO PATCH TESTING WITH DUST MITE AND YEASTS. Dermatitis, 2003, 14, 111.	0.8	0

#	Article	IF	Citations
235	Antimicrobial Effects of Photosensitized Silicon Phthalocyanine (Pc) 4. , 2016, , 521-530.		0
236	Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0054921.	1.4	0
237	Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes. Blood, 2018, 132, 5754-5754.	0.6	0
238	Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes. Blood, 2018, 132, 4627-4627.	0.6	0
239	Mycobiome Supporting Diet to Reduce Gastrointestinal (GI)Toxicity Associated with Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM). Blood, 2021, 138, 3948-3948.	0.6	0
240	Characterization of fungal mycobiome in bladder cancer.. Journal of Clinical Oncology, 2022, 40, 542-542.	0.8	0
241	Title is missing!. , 2020, 15, e0244246.		0
242	Title is missing!. , 2020, 15, e0244246.		0
243	Title is missing!. , 2020, 15, e0244246.		0
244	Title is missing!. , 2020, 15, e0244246.		0